Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Calendar
Upcoming events
01Jun
Annual General Meeting 2026
25Jun
Hansa Biopharma Capital Markets Day
22Jul
Interim Report for January-June 2026
Press releases
Our latest press releases
Hansa Biopharma’s CEO Renée Aguiar-Lucander named one of Sweden’s Most Influential Business Women of 2026
29/05/2026
Hansa Biopharma reports positive efficacy and safety results from Idefirix[®] European post authorization study in kidney transplantation
Regulatory press release
27/05/2026
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
25/05/2026
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Regulatory press release
19/05/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
